The 10-day RSI Oscillator for UTI moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 instances where the indicator moved out of the overbought zone. In 31 of the 39 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 68 cases where UTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UTI as a result. In 76 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence (MACD) for UTI just turned positive on November 10, 2026. Looking at past instances where UTI's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
UTI moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UTI crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +16.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in 259 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
UTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 183 of 250 cases where UTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. UTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: UTI's P/B Ratio (3.189) is slightly higher than the industry average of (1.158). UTI has a moderately high P/E Ratio (32.145) as compared to the industry average of (8.484). Projected Growth (PEG Ratio) (1.642) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (4.151) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (27.566).
ATTO | UTI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 34 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 99 | 68 | |
PRICE GROWTH RATING 1..100 | 34 | 61 | |
P/E GROWTH RATING 1..100 | 16 | 15 | |
SEASONALITY SCORE 1..100 | 41 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ATTO's Valuation (13) in the Miscellaneous Commercial Services industry is significantly better than the same rating for UTI (85). This means that ATTO’s stock grew significantly faster than UTI’s over the last 12 months.
UTI's Profit vs Risk Rating (67) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for ATTO (100). This means that UTI’s stock grew somewhat faster than ATTO’s over the last 12 months.
UTI's SMR Rating (68) in the Miscellaneous Commercial Services industry is in the same range as ATTO (99). This means that UTI’s stock grew similarly to ATTO’s over the last 12 months.
ATTO's Price Growth Rating (34) in the Miscellaneous Commercial Services industry is in the same range as UTI (61). This means that ATTO’s stock grew similarly to UTI’s over the last 12 months.
UTI's P/E Growth Rating (15) in the Miscellaneous Commercial Services industry is in the same range as ATTO (16). This means that UTI’s stock grew similarly to ATTO’s over the last 12 months.
| UTI | |
|---|---|
| RSI ODDS (%) | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 78% |
| Advances ODDS (%) | 10 days ago 78% |
| Declines ODDS (%) | 7 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 73% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATTO’s FA Score shows that 2 FA rating(s) are green while UTI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
UTI’s TA Score shows that 6 TA indicator(s) are bullish.
ATTO (@Biotechnology) experienced а -7.17% price change this week, while UTI (@Other Consumer Specialties) price change was -4.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -5.39%. For the same industry, the average monthly price growth was -12.15%, and the average quarterly price growth was -24.55%.
The average weekly price growth across all stocks in the @Other Consumer Specialties industry was -9.15%. For the same industry, the average monthly price growth was -22.68%, and the average quarterly price growth was -31.47%.
UTI is expected to report earnings on Feb 10, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Other Consumer Specialties (-9.15% weekly)‘Other Consumer Specialties’ represents an industry that typically sells durable consumer products, but do not have a classification in another category. The products include jewelry, smoke detectors, watches, collectibles and safety products. MSA Safety (makes products which enhances the safety and health of workers and protect facility infrastructures), Matthews International (memorialization business), Fitbit (makes wireless-enabled wearable technology devices that gauge data such as the number of steps walked, heart rate, quality of sleep), and Fossil Group (makes watches and accessories) have some of the largest market caps in this group.
A.I.dvisor tells us that ATTO and BTCT have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ATTO and BTCT's prices will move in lockstep.
| Ticker / NAME | Correlation To ATTO | 1D Price Change % | ||
|---|---|---|---|---|
| ATTO | 100% | +4.51% | ||
| BTCT - ATTO | 20% Poorly correlated | N/A | ||
| UTI - ATTO | 20% Poorly correlated | +0.82% | ||
| GPN - ATTO | 12% Poorly correlated | +0.35% | ||
| EFX - ATTO | 10% Poorly correlated | -0.35% | ||
| EVLV - ATTO | 9% Poorly correlated | +1.03% | ||
More | ||||
A.I.dvisor indicates that over the last year, UTI has been loosely correlated with LINC. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if UTI jumps, then LINC could also see price increases.
| Ticker / NAME | Correlation To UTI | 1D Price Change % | ||
|---|---|---|---|---|
| UTI | 100% | +0.82% | ||
| LINC - UTI | 66% Loosely correlated | -2.76% | ||
| AZZ - UTI | 49% Loosely correlated | -0.68% | ||
| APEI - UTI | 48% Loosely correlated | +3.91% | ||
| PRDO - UTI | 46% Loosely correlated | +1.25% | ||
| BV - UTI | 46% Loosely correlated | +0.46% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QIDX | 11.48 | 0.03 | +0.27% |
| Indexperts Quality Earnings Focused ETF (QIDX) | |||
| REMC | 22.74 | -0.02 | -0.08% |
| Columbia Research Enhanced Mid Cap ETF (REMC) | |||
| NAZ | 10.11 | -0.06 | -0.59% |
| Nuveen Arizona Quality Municipal Income Fund | |||
| XME | 87.37 | -1.82 | -2.04% |
| State Street SPDR S&P Metals & Mining ETF (XME) | |||
| CRAK | 54.40 | -1.83 | -3.25% |
| VanEck Oil Refiners ETF (CRAK) | |||